Therapeutic activity of a hematopoietic stem cell-delivered cell-penetrating frataxin in Friedreich’s ataxia models

May 1, 2026Cell Reports MedicineOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to evaluate the therapeutic potential of a frataxin peptide delivered via hematopoietic stem cells in Friedreich's ataxia models.
Hematopoietic stem and progenitor cells (HSPCs) were genetically modified to express frataxin peptide.
The modified cells were differentiated into macrophages to assess peptide secretion.
Long-term effects of the peptide on Friedreich's ataxia stabilization were analyzed.
HSPCs differentiated into functional macrophages that successfully secreted the frataxin peptide.
The therapy led to stabilization of Friedreich's ataxia in model systems, indicating potential for clinical application.

Demonstrates gene therapy's potential to stabilize Friedreich’s ataxia, suggesting effective treatment avenues.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Pido-Lopez et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share